Acute ethanol administration increases striatal dopamine release and decreases cerebral glucose metabolism. The A1 allele of the ANKK1 TaqIa polymorphism is associated with lower dopaminergic tone and greater risk for alcoholism, but the mechanisms are unclear. We hypothesized that ethanol would be more reinforcing in men with the A1 allele (A1+) than in men without it (A1−), as indicated by decreased anxiety and fatigue and altered activity in associated brain regions. In a pilot study, A1+ and A1− men (6/group) drank ethanol (0.75 ml/kg) or placebo beverages on each of 2 days. Positron emission tomography with [F-18] fluorodeoxyglucose (FDG) was used to assess regional cerebral glucose metabolism as a measure of relative brain activity while participants performed a vigilance task. Significant findings were as follows: Ethanol decreased anxiety and fatigue in A1+ men but increased them in A1-men. Ethanol increased activity in the striatum and insula of A1+ men, but reduced activity in the anterior cingulate of A1-men. Reduced anxiety and fatigue in A1+ men were significantly associated with greater activity within a right orbitofrontal region previously implicated in cognitive control, and less activity in structures associated with anxiety (amygdala), fatigue (thalamus), and craving/reinforcement (striatum). In contrast, anxiety and fatigue changes were unrelated to brain activity in A1− men. Although these results require replication in a larger sample, alcoholinduced negative reinforcement may explain the greater risk for alcoholism associated with the A1 allele.
Introduction
A growing literature points to an important role of genotype in vulnerability to substance abuse, with much of this work centering on the role of central dopamine systems in motivation and reinforcement (Volkow et al., 2007) . Reduced density of striatal D2 dopamine receptors has been associated with reinforcer-induced impulsivity in rats (Dalley et al., 2007) , and with presence of the TaqIA A1 allele of the ANKK1 gene (previously reported as located in the D2 dopamine receptor gene) (Neville et al., 2004) in humans, both through in vitro (Noble et al., 1991; Thompson et al., 1997) and in vivo (Jonsson et al., 1999; Pohjalainen et al., 1998) studies. Although A1 prevalence differs between ethnic groups (Barr and Kidd, 1993) , raising the possibility of stratification bias, studies both across and within diverse ethnic groups have reported robust associations of the polymorphism first with misuse of alcohol (Blum et al., 1990) and subsequently with other forms of substance abuse (Li et al., 2004a; Noble 2003; Young et al., 2004) . In a meta-analysis of 3329 Caucasian adults, the prevalence of the Al allele (AlAl and A1A2 genotypes) was significantly higher (P = 1.54 × 10 These associations have led to the hypothesis that the lower dopaminergic tone of the mesocorticolimbic reinforcement circuits in individuals with the A1 allele produces reinforcement deficiencies or anhedonia (Blum et al., 2000; Noble, 2000) . Low D2 function is thought to 1) increase the reward value of direct D2 agonists, including all drugs of abuse, 2) decrease the reward value of less potent natural reinforcers, and 3) decrease the capacity for frontocortical inhibition, all of which contribute to compulsive drug taking (Volkow et al., 2004) .
A report consistent with this view indicated that individuals with the A1 allele are characterized by less activation of the mesocorticolimbic reinforcement system than those without the allele (Cohen et al., 2005) . In contrast, treatment with the D2 agonist bromocriptine enhanced 
